Gland Pharma Ltd (GLAND) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Gland Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Gland Pharma receives approval for Methylprednisolone Acetate Injectable Suspension USP, Single Dose and Multiple Dose Vials
Press Release · 03 Nov 2026, 5:01 pm
Gland Pharma Secures USFDA Approval for Generic Depo-Medrol Injectable Suspension Gland Pharma received USFDA approval for its ANDA for Methylprednisolone Acetate Injectable Suspension USP across single-dose (40 mg/mL, 80 mg/mL) and multiple-dose vials (200 mg/5 mL, 400 mg/10 mL, and 400 mg/5 mL). The product is bioequivalent and therapeutically equivalent to Pfizer's reference listed drug, Depo-Medrol Injectable Suspension, which treats various allergic, dermatologic, endocrine, and respiratory disorders. According to IQVIA data, Methylprednisolone injection generated US sales of approximately USD 214 million for the twelve months ending Aug'26.
Appointment of Mr. Ajay Sahni as the Chief Executive Officer of Gland Pharma International Pte. Ltd (Wholly owned subsidiary of Gland Pharma Limited)
Change in Management · 30 Oct 2026, 10:05 pm
Gland Pharma Appoints Ajay Sahni as CEO of Gland Pharma International Gland Pharma Limited has appointed Ajay Sahni as Chief Executive Officer of its wholly owned subsidiary, Gland Pharma International Pte. Ltd. (Gland Singapore), effective 2nd Nov'26. Sahni will oversee the Cenexi business, a wholly owned step-down subsidiary, and report directly to the CEO of Gland Pharma Limited. Bringing over 36 years of experience across FMCG and pharmaceuticals, Sahni has previously held senior leadership and managing director roles at Sanofi, Ferring Pharmaceuticals, Pinewood Healthcare, and Wockhardt subsidiaries across Europe, the US, and Asia.
Conclusion of USFDA Unannounced Inspection at Company''s Formulation Facility at Dundigal, Hyderabad
Others (Uncategorized) · 23 Oct 2026, 9:51 pm
Gland Pharma Dundigal Facility Receives Four USFDA Form 483 Observations The USFDA concluded an unannounced cGMP inspection at Gland Pharma Limited’s Dundigal formulation facility, conducted from 12th Oct'26 to 23rd Oct'26, issuing Form 483 with four observations. The company confirmed that all observations are procedural in nature, are neither repeated nor related to data integrity, and have no quantifiable impact on financials or operations. Corrective and preventive actions (CAPA) will be submitted to the regulator within the stipulated timeline.
GLAND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 06 Nov 2026, 5:30 am
Q2FY27 Earnings Call Intimation
Intimation · 06 Nov 2026, 6:30 pm
Gland Pharma Schedules Q2 FY27 Earnings Conference Call Gland Pharma Limited will host an earnings conference call for investors and analysts on 6th Nov'26 at 18:30 IST for 60 minutes. The management team will discuss the company's financial performance and business updates for the quarter and half-year ended 30th Sep'26 (Q2 FY27). Universal dial-in access numbers include +91 22 6280 1516 and +91 22 7115 8875, alongside international toll-free options. The audio recording and transcript will subsequently be made available on the company’s official website.
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Unaudited Financial Results for ....
Intimation · 06 Nov 2026, 5:30 am
Gland Pharma Schedules Board Meeting for Q2 FY27 Financial Results Gland Pharma Limited will hold a Board of Directors meeting on 6th Nov'26 to consider and approve its unaudited standalone and consolidated financial results for the quarter and half year ended 30th Sep'26. The company will also host an earnings call for investors and analysts on 6th Nov'26 at 18:30 IST. Consequently, the insider trading window, closed since 1st Oct'26, is scheduled to reopen on 9th Nov'26.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 06 Nov 2026, 5:30 am
Resignation of Mr. Wenjie Zhang as a Non-Executive & Non-Independent Director and Appointment of Mr. Xingli Wang as an Additional Director (Non-Executive and Non-Independent Director)
Change in Management · 01 Oct 2026, 9:24 pm
Gland Pharma Approves $21M US Investment and Board Changes Gland Pharma’s board approved a USD 21 million cash investment in wholly owned subsidiary Gland Pharma USA Inc. to acquire a 60% stake in US-based Novelstar Pharma Inc. by 31st Oct'26, expanding its US market footprint. Fosun Pharma USA Inc. will hold the remaining 40% in Novelstar. Additionally, Non-Executive Non-Independent Director Wenjie Zhang resigned effective 1st Oct'26 due to preoccupations, and Xingli Wang, President of Fosun Pharma, was appointed as an Additional Director (Non-Executive Non-Independent) on the same date.
Investment by Gland Pharma Limited in Gland Pharma USA Inc. and Investment by Gland Pharma USA Inc. into Novelstar Pharma Inc.
Others (Uncategorized) · 01 Oct 2026, 9:21 pm
Gland Pharma Approves USD 21 Million Investment in US Expansion Gland Pharma’s Board approved an investment of USD 21m in its wholly-owned subsidiary, Gland Pharma USA Inc., on 1st Oct'26 to acquire a 60% stake in newly incorporated Novelstar Pharma Inc. for USD 21m in cash by 31st Oct'26, expanding its US business. Fosun Pharma USA Inc. will hold the remaining 40%. Additionally, Wenjie Zhang resigned as Non-Executive Director effective 1st Oct'26, and Xingli Wang was appointed as Additional Non-Executive Director.
Outcome of Board Meeting held on October 01, 2026
Others (Uncategorized) · 01 Oct 2026, 9:15 pm
Gland Pharma Approves $21M US Investment and Board Reconstitution Gland Pharma approved a USD 21m cash investment in wholly-owned subsidiary Gland Pharma USA Inc. to subscribe to a 60% stake in newly incorporated Novelstar Pharma Inc. by 31st Oct'26, expanding its US footprint alongside Fosun Pharma USA Inc. (40% stake). Post-transaction, Novelstar will become a step-down subsidiary with USD 35m in share capital. Additionally, effective 1st Oct'26, Wenjie Zhang resigned as Non-Executive Director, and Xingli Wang was appointed as Additional Non-Executive Director, prompting reconstitutions across key board committees.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial Pte Ltd
Acquisition/ Disposal of Shares · 01 Oct 2026, 2:26 pm
Fosun Pharma Sells 6% Stake in Gland Pharma via Open Market Promoter Fosun Pharma Industrial Pte. Ltd. sold 98,97,000 equity shares, representing a 6.00% stake (5.95% on a diluted basis) in Gland Pharma Limited via open market transactions on 4th Sep'26. Following the disposal, Fosun Pharma's shareholding in Gland Pharma declined from 8,53,93,894 shares (51.76% of total voting capital; 51.36% diluted) to 7,54,96,894 shares (45.76% of total voting capital; 45.41% diluted).
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund
Acquisition/ Disposal of Shares · 30 Sept 2026, 5:09 pm
Mirae Asset Mutual Fund Trims Stake in Gland Pharma to 2.95% Mirae Asset Mutual Fund reduced its holding in Gland Pharma Limited by selling 57,842 equity shares (0.04% of total voting capital) via an open market transaction on 28th Sep'26. Following the sale, the fund's equity holding decreased from 4,930,033 shares (2.99% of total voting capital and 2.96% of diluted capital) to 4,872,191 shares, representing 2.95% of total voting capital and 2.92% of total diluted share capital.
Gland Pharma Limited has informed the Exchange about acquisition of 100% of the equity share capital of Gland Pharma USA Inc. , a wholly-owned step down subsidiary of the Company, from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company
Outcome · 13 Sept 2026, 10:07 pm
Acquisition of Gland Pharma USA Inc., a wholly-owned Step down subsidiary from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company
Others (Uncategorized) · 13 Sept 2026, 10:02 pm
Gland Pharma Approves Internal Corporate Restructuring to Direct US Subsidiary Ownership Gland Pharma Limited's Board approved the 100% equity acquisition of step-down subsidiary Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd. for a cash consideration of USD 5,01,208. The transaction converts Gland US into a direct wholly-owned subsidiary to remove corporate layers and streamline operations, with no material business impact. Incorporated in Mar'22 for pharma marketing and distribution, Gland US posted FY26 turnover of Nil (FY25: USD 87,342; FY24: USD 4,83,808). The transaction is slated for completion by 31st Oct'26.
Outcome of Board Meeting
Others (Uncategorized) · 13 Sept 2026, 9:57 pm
Gland Pharma Approves Full Acquisition of US Subsidiary to Streamline Corporate Structure Gland Pharma Limited approved the acquisition of 100% equity share capital of Gland Pharma USA Inc. from its wholly-owned subsidiary, Gland Pharma International Pte. Ltd, for a cash consideration of USD 501,208. The transaction converts Gland US from a step-down unit into a direct wholly-owned subsidiary to eliminate corporate layers and streamline operations, with no material impact on business. Gland US reported nil turnover in FY26 (USD 87,342 in FY25). The arm’s-length related-party transaction is scheduled for completion by 31st Oct'26.
Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 13, 2026.
Outcome · 13 Sept 2026, 9:57 pm
Gland Pharma to Direct-Own US Subsidiary via Internal Restructuring Gland Pharma Limited's board approved the 100% equity acquisition of step-down subsidiary Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd for a cash consideration of USD 5,01,208 on 13th Sep'26. The transaction transitions Gland US into a direct wholly-owned subsidiary to eliminate corporate holding layers and streamline organizational structure, with expected completion by 31st Oct'26. Gland US, engaged in pharma marketing and distribution, reported nil turnover in FY26, following USD 87,342 in FY25 and USD 4,83,808 in FY24.
Allotment of 44,193 Equity Shares on exercise of ESOPs
Others (Uncategorized) · 13 Sept 2026, 9:09 pm
Gland Pharma Allots 44,193 Equity Shares Under ESOP Schemes Gland Pharma Limited allotted 44,193 equity shares of face value Re. 1 each on 13th Sep'26 upon the exercise of employee stock options. This includes 42,393 shares allotted to 35 employees under ESOP 2025 and 1,800 shares to one employee under ESOP 2019. Consequently, the company's paid-up share capital increased to Rs. 165,010,854 comprising 165,010,854 equity shares. Additionally, the ESOP Compensation Committee approved the formal closure and winding up of the ESOP 2019 scheme with immediate effect as all eligible options have been fully exercised or lapsed.
Grant of Stock Options under Gland Pharma Employee Stock Option Scheme, 2025
Others (Uncategorized) · 13 Sept 2026, 9:04 pm
Gland Pharma Approves Grant of 5.90 Lakh Stock Options Under ESOP 2025 Gland Pharma's ESOP Compensation Committee approved the grant of 5,90,249 stock options to 124 employees under the ESOP 2025 scheme on 13th Sep'26. The grant comprises 3,89,564 options priced at INR 1,461.15 per share (50% of the NSE closing price on 11th Sep'26) and 2,00,685 options at a face value of INR 1 per share. The options follow a three-year vesting schedule: 34% on 13th Sep'27, 33% on 13th Sep'28, and 33% on 13th Sep'29, exercisable within two years from each vesting date.
Board Comments on fines levied by Exchanges
Others (Uncategorized) · 13 Sept 2026, 8:57 pm
Gland Pharma Settles Stock Exchange Fines Over Director Appointment Delay Gland Pharma Limited addressed exchange-levied fines of ₹70,000 each from BSE and NSE regarding a 34-day technical breach of Regulation 17(1A) under SEBI LODR. The delay occurred while securing shareholder approval via postal ballot for appointing Non-Executive Independent Director Mr. William Keller, aged over 75, appointed on 15th Jun'26. Shareholders approved the special resolution on 18th Jul'26. The board reviewed the issue on 13th Sep'26, and the company has suo motu paid the full fine upfront to close the matter.
Schedule of Investor Meetings
Intimation · 10 Sept 2026, 11:14 pm
Gland Pharma Schedules Institutional Investor and Analyst Meetings in Sep'26 Gland Pharma Limited announced its schedule of institutional investor and analyst interactions under SEBI LODR Regulations. The company will conduct one-on-one meetings with East Bridge Capital on 16th Sep'26, followed by sessions with IIFL Capital and Antique Broking on 17th Sep'26. Additionally, Gland Pharma is scheduled to participate in a group meeting organized by Nomura on 25th Sep'26. All scheduled interactions remain subject to change based on exigencies from either the investors, analysts, or the company.
Investor Meet Intimation
Intimation · 09 Sept 2026, 1:16 am
Gland Pharma Schedules One-on-One Investor Meeting with DSP Mutual Fund Gland Pharma Limited announced, pursuant to SEBI Listing Regulations, a scheduled one-on-one institutional investor meeting with DSP Mutual Fund set for 11th Sep'26. The company noted that the schedule remains subject to changes arising from unforeseen exigencies from either party.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial Pte Ltd
Acquisition/ Disposal of Shares · 08 Sept 2026, 6:16 pm
Fosun Pharma Sells 6% Stake in Gland Pharma via Open Market Promoter entity Fosun Pharma Industrial Pte. Ltd. sold 98,97,000 equity shares, representing a 6.00% stake (5.95% on a diluted basis) in Gland Pharma Limited via open market transactions on 4th Sep'26. Following the disposal, Fosun Pharma's holding in Gland Pharma declined from 8,53,93,894 shares (51.76% total voting capital; 51.36% diluted) to 7,54,96,894 shares, or 45.76% of total voting capital (45.41% diluted).
Schedule of Investor Meet Intimation
Intimation · 04 Sept 2026, 8:24 pm
Gland Pharma Schedules One-on-One Meeting with Kotak Mutual Fund Gland Pharma Limited has scheduled a one-on-one meeting with Kotak Mutual Fund on 9th Sep'26, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule remains subject to changes arising from any exigencies on the part of the fund, analyst, or the company.
Conclusion of USFDA Inspection at Company''s Facilities situated at Visakhapatnam
Others (Uncategorized) · 01 Sept 2026, 9:19 pm
Gland Pharma Receives Zero Form 483 Observations from USFDA Gland Pharma announced the conclusion of a USFDA inspection at its VSEZ Sterile Oncology Formulations and API Facility in Visakhapatnam. The routine Good Manufacturing Practice (GMP) inspection, conducted from 24th Aug’26 to 1st Sep’26, concluded with ZERO (0) Form 483 observations. This favorable outcome is a significant positive, indicating compliance with US regulatory standards and mitigating risks of supply disruptions from this key facility. The company stated there is no financial or operational impact.
Schedule of Investor Meets
Intimation · 31 Aug 2026, 11:26 pm
Gland Pharma Announces September 2026 Investor Meeting Schedule Gland Pharma announced its Sep'26 investor meeting schedule. One-on-one meetings are slated with Carnelian Capital (Sep 03), First Ray Capital (Sep 04), WCM Investment (arranged by Jefferies, Sep 04), and LIC MF (arranged by 360One, Sep 07). The company will also attend the BofA Securities 2026 Asia Pacific Conference (Sep 21-22). Group meetings are scheduled with ICICI Securities (Sep 18) and JP Morgan (Sep 24). The disclosed schedule is subject to potential changes.